For many years, bleeding has been perceived as an unavoidable consequence of strategies
aimed at reducing thrombotic complications in patients undergoing percutaneous coronary …

Contemporary evidence supports device-based transcatheter interventions for the
management of patients with structural heart disease. These procedures, which include …

The aim of this collaborative document is to provide an update for clinicians on best
antithrombotic strategies in patients with aortic and/or peripheral arterial diseases …

Aims Patients at high bleeding risk (HBR) represent a prevalent subgroup among those
undergoing percutaneous coronary intervention (PCI). Early aspirin discontinuation after a …

Background The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous
coronary intervention (PCI) among patients at high bleeding risk (HBR) is unknown …

Multiple guidelines and consensus papers have addressed the role of antithrombotic
strategies in patients with established coronary artery disease (CAD). Since evidence and …

Background Gastrointestinal bleeding is the most frequent major complication of antiplatelet
therapy. In patients at low bleeding risk, however, clinically overt gastrointestinal bleeding is …

Background The identification of bleeding risk factors in patients undergoing percutaneous
coronary intervention (PCI) is essential to inform subsequent management. Whether clinical …

Importance Abbreviated dual antiplatelet therapy (DAPT) reduces bleeding with no increase
in ischemic events in patients at high bleeding risk (HBR) undergoing percutaneous …

For almost two decades, 12-month dual antiplatelet therapy (DAPT) in acute coronary
syndrome (ACS) has been the only class I recommendation on DAPT in American and …